Patents by Inventor Matthew V. Lorenzi

Matthew V. Lorenzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230030983
    Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
    Type: Application
    Filed: March 18, 2022
    Publication date: February 2, 2023
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Jayaprakash KARKERA, Suso Jesus PLATERO, Raluca VERONA, Matthew V. LORENZI
  • Publication number: 20200108141
    Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
    Type: Application
    Filed: October 23, 2019
    Publication date: April 9, 2020
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Jayaprakash KARKERA, Suso Jesus PLATERO, Raluca VERONA, Matthew V. LORENZI
  • Patent number: 10478494
    Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: November 19, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Jayaprakash Karkera, Suso Jesus Platero, Raluca Verona, Matthew V. Lorenzi
  • Publication number: 20160287699
    Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
    Type: Application
    Filed: March 24, 2016
    Publication date: October 6, 2016
    Inventors: Jayaprakash KARKERA, Suso Jesus Platero, Raluca Verona, Matthew V. Lorenzi
  • Patent number: 7521044
    Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.
    Type: Grant
    Filed: August 1, 2006
    Date of Patent: April 21, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald G. Jackson, Matthew V. Lorenzi, Liana M. Lee, John N. Feder
  • Patent number: 7297493
    Abstract: A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: November 20, 2007
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Matthew V. Lorenzi, Toru Miki
  • Patent number: 7199227
    Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: April 3, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald G. Jackson, Matthew V. Lorenzi, Ricardo M. Attar, Marco Gottardis, Liana M. Lee, John N. Feder
  • Patent number: 7138246
    Abstract: Methods for determining whether a test agent inhibits a 17?-HSD3, the methods comprising: obtaining a recombinant host cell that expresses the 17?-HSD3; obtaining a reaction mixture comprising the 17?-HSD3, androstenedione, and the test agent; measuring the amount of testosterone in the reaction mixture by a scintillation proximity assay (SPA) using SPA beads conjugated with a testosterone-specific antibody, wherein when the amount of testosterone is lower in the presence of a test agent than in the absence of the test agent, the test agent is identified as an inhibitor of the 17?-HSD3.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: November 21, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Matthew V. Lorenzi, Thomas Spires, Dan You, Roberto Weinmann, Marco Gottardis
  • Patent number: 6831170
    Abstract: A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: December 14, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Matthew V. Lorenzi, Toru Miki
  • Publication number: 20040122080
    Abstract: Chemotherapeutic combinations of selected cytotoxic agents and RAR&agr;/&bgr; selective agonists or RAR pan antagonists for use in treating cancer and lowering the effective cytotoxic dose of the selected cytotoxic agent are provided.
    Type: Application
    Filed: February 19, 2004
    Publication date: June 24, 2004
    Inventors: Valerie S Vivat-Hannah, Matthew V Lorenzi, Marco M Gottardis, Fred Christopher Zusi
  • Publication number: 20030224454
    Abstract: Human solute carrier family 7, member 11 (hSLC7A11) polynucleotides and polypeptides. Also provided are expression vectors, recombinant host cells and processes for producing recombinant host cells, processes for producing said polypeptides, and methods for identifying receptors that are capable of binding to a solute carrier family 7, member 11 molecule.
    Type: Application
    Filed: May 29, 2003
    Publication date: December 4, 2003
    Inventors: Rolf Peter Ryseck, Matthew V. Lorenzi, David K. Bol
  • Publication number: 20030212260
    Abstract: A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.
    Type: Application
    Filed: June 12, 2003
    Publication date: November 13, 2003
    Applicant: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Matthew V. Lorenzi, Toru Miki
  • Publication number: 20030161830
    Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.
    Type: Application
    Filed: June 14, 2002
    Publication date: August 28, 2003
    Inventors: Donald G. Jackson, Matthew V. Lorenzi, Ricardo M. Attar, Marco Gottardis
  • Patent number: 6608181
    Abstract: A novel gene designated as FRAG1 and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: August 19, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Matthew V. Lorenzi, Toru Miki
  • Publication number: 20020032310
    Abstract: A novel gene designated as FRAG1 and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.
    Type: Application
    Filed: August 29, 2001
    Publication date: March 14, 2002
    Applicant: The Govt. of the U.S.A., The Secretary of the Department of Health and Human Services
    Inventors: Matthew V. Lorenzi, Toru Miki
  • Patent number: 6323316
    Abstract: A novel gene designated as FRAG 1 and its encoded protein are disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: November 27, 2001
    Assignee: The United States of America as represented by the Secretary of the Department of and Human Services
    Inventors: Matthew V. Lorenzi, Toru Miki